Get the Stockscreener App
14.94
5.71%
-0.83
Arrowhead Pharmaceuticals Inc stock is traded at $14.94, with a volume of 294.14K.
It is down -5.71% in the last 24 hours and down -22.19% over the past month.
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
See More
Previous Close:
$15.77
Open:
$15.68
24h Volume:
294.14K
Relative Volume:
0.18
Market Cap:
$1.90B
Revenue:
$181.74M
Net Income/Loss:
$-599.49M
P/E Ratio:
-2.982
EPS:
-5.01
Net Cash Flow:
$-604.32M
1W Performance:
-15.85%
1M Performance:
-22.19%
6M Performance:
-30.81%
1Y Performance:
-47.99%
1-Day Range:
$14.82
$15.78
1-Week Range:
$14.22
$17.58
52-Week Range:
$14.22
$30.41
Arrowhead Pharmaceuticals Inc Stock (ARWR) Company Profile
Name
Arrowhead Pharmaceuticals Inc
Sector
Industry
Phone
626-696-4702
Address
177 E COLORADO BLVD, PASADENA, CA
Compare ARWR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARWR
Arrowhead Pharmaceuticals Inc
|
14.93 | 1.90B | 181.74M | -599.49M | -604.32M | -5.01 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.55 | 130.96B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
680.26 | 75.53B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
577.94 | 35.07B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.88 | 31.72B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
249.54 | 26.76B | 3.32B | -860.46M | -1.04B | -8.32 |
Arrowhead Pharmaceuticals Inc Stock (ARWR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-05-24 | Initiated | Goldman | Neutral |
| Dec-04-23 | Initiated | BofA Securities | Buy |
| Sep-19-23 | Initiated | Citigroup | Neutral |
| Jul-21-23 | Initiated | TD Cowen | Outperform |
| May-12-23 | Downgrade | SVB Securities | Outperform → Market Perform |
| Apr-26-23 | Initiated | SMBC Nikko | Outperform |
| Apr-12-23 | Upgrade | SVB Securities | Market Perform → Outperform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Sep-09-22 | Initiated | Morgan Stanley | Equal-Weight |
| May-11-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Jan-19-22 | Resumed | Goldman | Buy |
| Aug-06-21 | Reiterated | Chardan Capital Markets | Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-05-21 | Reiterated | H.C. Wainwright | Buy |
| Dec-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-16-20 | Initiated | UBS | Buy |
| Nov-19-20 | Initiated | Citigroup | Buy |
| May-13-20 | Initiated | RBC Capital Mkts | Outperform |
| May-08-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Apr-15-20 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Mar-24-20 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Mar-17-20 | Initiated | Goldman | Neutral |
| Jan-21-20 | Initiated | SVB Leerink | Underperform |
| Dec-13-19 | Initiated | Oppenheimer | Perform |
| Nov-29-19 | Reiterated | Chardan Capital Markets | Buy |
| Nov-27-19 | Reiterated | B. Riley FBR | Buy |
| Nov-25-19 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Oct-24-19 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-22-19 | Reiterated | Chardan Capital Markets | Buy |
| Oct-03-19 | Initiated | Robert W. Baird | Outperform |
| Sep-07-18 | Upgrade | B. Riley FBR | Neutral → Buy |
| Sep-06-18 | Reiterated | Chardan Capital Markets | Buy |
| Aug-08-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Jul-02-18 | Reiterated | Chardan Capital Markets | Buy |
View All
Arrowhead Pharmaceuticals Inc Stock (ARWR) Latest News
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Sold by US Bancorp DE - Defense World
Bank of New York Mellon Corp Sells 36,341 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead stock holds Buy rating, $80 target from H.C. Wainwright By Investing.com - Investing.com UK
Arrowhead Pharmaceuticals Stock Falls After Early-Stage Data From RNA-Based Therapeutic For Kidney Diseases - AOL
Institutional investors may adopt severe steps after Arrowhead Pharmaceuticals, Inc.'s (NASDAQ:ARWR) latest 4.2% drop adds to a year losses - Simply Wall St
Buy Rating for Arrowhead Pharmaceuticals Driven by Promising ARO-C3 Trial Results and Strategic Pipeline Advancements - TipRanks
Arrowhead Pharmaceuticals Stock Dips Despite Promising Study - TipRanks
Mutual of America Capital Management LLC Sells 1,519 Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals Announces Topline Results from Part 2 of Phase 1/2 Study of ARO-C3 in Patients with IgA Nephropathy - BioSpace
Arrowhead Pharmaceuticals Says Study for Complement-Mediated Disease Therapy Shows C3 Reduction in Patients - Marketscreener.com
Arrowhead Pharma Reports Positive Topline Data From Phase 1/2 Study Of ARO-C3 - Nasdaq
Arrowhead Pharmaceuticals Announces Topline Results From Part 2 Of Phase 1/2 Study Of Aro-C3 In Patients With IgA Nephropathy - Marketscreener.com
Arrowhead Clinical Trial: 87% C3 Reduction in IgA Nephropathy Patients - StockTitan
Arrowhead Pharmaceuticals, Inc. to Host Earnings Call - ACCESS Newswire
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals Showcases Two Clinical-Stage RNAi-Based Candidates to Treat Obesity and Metabolic Diseases - Lelezard
Arrowhead Pharmaceuticals Presents Data on Two Clinical-Stage Candidates for Obesity Treatment - Marketscreener.com
Arrowhead advances RNAi obesity treatments in clinical trials By Investing.com - Investing.com UK
Can These Two RNAi Drugs Revolutionize Obesity Treatment? Arrowhead's Promising Data - StockTitan
Arrowhead Pharmaceuticals CEO sells $5.27 million in stock - Investing.com
Familial Chylomicronemia Syndrome Market to Expand - openPR
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Position Trimmed by Principal Financial Group Inc. - Defense World
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Brokerages - Defense World
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patient-Centric Resources for Those Affected by Familial Chylomicronemia Syndrome (FCS) - Cadillac News
How Arrowhead's New FCS Resources Could Transform Life for Rare Disease Patients - StockTitan
Arrowhead Pharmaceuticals Launches on Rare Disease Day New Patie - GuruFocus.com
Rhumbline Advisers Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Objective long/short (ARWR) Report - Stock Traders Daily
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity - The Bakersfield Californian
Can Arrowhead's New Obesity Drug Outperform GLP-1s? Preclinical Data Shows Key Advantage - StockTitan
Van ECK Associates Corp Raises Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Empowered Funds LLC Takes $268,000 Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
12 Most Oversold Healthcare Stocks to Buy Now - Insider Monkey
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions (NASDAQ:ARWR) - Seeking Alpha
Fat, not muscle: drugmakers in race for next weight-loss breakthrough - Reuters
Zacks Small Cap Has Pessimistic Outlook of ARWR Q2 Earnings - MarketBeat
Analysts Offer Predictions for ARWR Q2 Earnings - MarketBeat
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough By Investing.com - Investing.com South Africa
Arrowhead Pharmaceuticals' SWOT analysis: RNAi pioneer's stock poised for potential breakthrough - Investing.com
Arrowhead Pharmaceuticals' (ARWR) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
B. Riley Reaffirms Buy Rating for Arrowhead Pharmaceuticals (NASDAQ:ARWR) - MarketBeat
Guidewire Software set to join S&P MidCap 400; Arrowhead Pharmaceuticals to join S&P SmallCap 600 - MSN
Leerink Partnrs Analysts Raise Earnings Estimates for ARWR - MarketBeat
Yousif Capital Management LLC Lowers Stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) - Defense World
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock Price Down 5%What's Next? - MarketBeat
Arrowhead and Sarepta close $500 million licensing deal - MSN
When (ARWR) Moves Investors should Listen - Stock Traders Daily
Arrowhead Pharmaceuticals (NASDAQ:ARWR) Earns Outperform Rating from Royal Bank of Canada - MarketBeat
Arrowhead sees potential $2-3B annual sales for plozasiran in SHTG market by 2026 - MSN
10 Health Care Stocks With Whale Alerts In Today's Session - Benzinga
Arrowhead Pharmaceuticals Inc Stock (ARWR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Arrowhead Pharmaceuticals Inc Stock (ARWR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Anzalone Christopher Richard | Chief Executive Officer |
Mar 04 '25 |
Option Exercise |
7.75 |
133,333 |
1,033,331 |
4,073,802 |
| Anzalone Christopher Richard | Chief Executive Officer |
Mar 03 '25 |
Sale |
18.03 |
166,667 |
3,005,006 |
3,907,135 |
| Anzalone Christopher Richard | Chief Executive Officer |
Mar 04 '25 |
Sale |
17.02 |
133,333 |
2,269,328 |
3,773,802 |
5.68%
0.28%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):